Levan Darjania

Chief Science Officer

Levan is an accomplished scientist and manager with over 26 years in biotech and drug development (small and large molecules as well as natural products) industries. His experience encompasses the successful leading numerous preclinical and clinical ADME, DMPK, pharmacokinetics, toxicokinetics and bioanalysis projects, building and managing ADME/PK/Tox/TK facilities within biotech companies, acquiring and training professional R&D teams, managing project deliverables and budgets for internal and external collaborations as well as a global CRO management, close monitoring of GLP-compliant IND-enabling studies, authoring IND-related Module 4 and Module 2 sections for FDA filing, and providing input on strategic decision making and project liability toward the advancement of clinical candidates to phase I/II. He also worked with the Private Investment Group to oversee the Global Project Analysis, R&D activities, due diligence process and scientific communications for the portfolio companies focused on the nutraceutical (cannabis-hemp plant derived cannabinoids), pharmaceutical, medical device/drug combination product and technology platform development.